PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.52
Negative P/E while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize path to profitability versus peers.
6.93
P/S 1.1-1.25x Drug Manufacturers - Specialty & Generic median of 5.80. John Neff would demand superior growth or margins to justify premium.
0.39
P/B less than half the Drug Manufacturers - Specialty & Generic median of 1.12. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
-50.64
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
-81.18
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
0.39
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 1.13. Joel Greenblatt would investigate if this discount is justified.
-7.10%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -0.00%. Seth Klarman would investigate path to profitability.
-1.97%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.